Mumbai: Rx Propellant, a science and R&D infrastructure platform established by Actis, a leading growth market investor in sustainable infrastructure and part of General Atlantic, has announced the appointment of Ashish Singh as its Chief Executive Officer and Managing Director. Ashish assumed the role a few months earlier and has since been steering the company’s next phase of growth as it builds institutional-grade laboratory infrastructure across India’s key science clusters.
Ashish transitions into a full-time executive leadership position from Actis, where he previously served as Head of Real Estate Investments for India and Southeast Asia. During his tenure, he played a pivotal role in the creation, strategic direction and growth of Rx Propellant, working closely with the platform to position it as a credible builder-operator of science infrastructure in India.
With more than three decades of experience across real estate, investment management and business consulting, Ashish has built and scaled institutional platforms across emerging asset classes. Prior to Actis, he held senior leadership roles at Standard Chartered Bank, Tishman Speyer and Cushman & Wakefield, advising and investing across both traditional and new-economy real estate sectors.
His appointment reflects Actis’ long-term conviction in Rx Propellant and signals a strategic shift toward strengthening execution capabilities, scale and leadership depth as the company pursues an ambitious growth roadmap and expands its national footprint.
Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said, “Ashish has been deeply involved in shaping Rx Propellant since its formation and brings a rare combination of investment discipline, operating perspective and long-term vision. As the platform enters its next phase of growth, his leadership will be instrumental in building Rx Propellant into a market-defining institution for strategic science infrastructure solutions in India.”
Commenting on his appointment, Ashish Singh, CEO & Managing Director, Rx Propellant, said, “Rx Propellant has built a strong foundation anchored in sector expertise, design, sustainability and execution at scale. I look forward to working closely with our teams and partners to deepen our presence across key clusters, deliver globally benchmarked campuses, and build a platform that supports innovation and long-term value creation.”
Under Ashish’s leadership, Rx Propellant will continue to focus on developing large-format, sustainable campuses designed to support R&D, innovation and scale-up for both global and Indian science-led enterprises.
The company currently has a development portfolio of approximately 4 million square feet across Hyderabad and Navi Mumbai, along with a robust pipeline for future expansion. Rx Propellant continues to partner with leading pharmaceutical, biotechnology and research-driven organisations seeking high-quality, scalable laboratory environments aligned with global standards.
